iifl-logo

Sun Pharmaceuticals Industries Ltd Dividend

1,708.45
(0.59%)
Apr 2, 2025|11:19:56 AM

Sun Pharma.Inds. CORPORATE ACTIONS

02/04/2024calendar-icon
02/04/2025calendar-icon
PurposeAnnouncement DateEx-DateRecord DateDividend AmountDividend per ShareRemark
Dividend31 Jan 20256 Feb 20256 Feb 202510.51050Interim
Board approved interim dividend for FY 2024-25
Dividend22 May 202412 Jul 202412 Jul 20245500Final
Board of Directors of the Company was held today i.e. May 22, 2024 Final dividend of Rs. 5/- (Rupees Five only) per equity share of Re. l/- (Rupee One only) each is recommended to the shareholders for their approval at the ensuing Annual General Meeting of the Company. Final dividend, once approved by the shareholders, shall be to be paid within the prescribed timeline under the Companies Act, 2013.

Sun Pharma.Inds.: Related News

Sun Pharma to Acquire Nasdaq-Listed Checkpoint Therapeutics for $355 Million
10 Mar 2025|10:46 AM

The deal is expected to be completed in the second quarter of 2025, subject to customary closing conditions and regulatory approvals.

Read More
Sun Pharma Q3 Profit Jumps 19% YoY, Declares ₹10.50 Dividend
31 Jan 2025|10:17 PM

An interim dividend of ₹10.50 on the face value per share for FY25 has been declared.

Read More
Sun Pharma reports Q2 net profit at ₹3,040 Crore
29 Oct 2024|10:30 AM

Sun Pharma has bolstered its speciality pipeline with a partnership with Philogen to commercialise late-stage candidate Fibromun.

Read More
Sun Pharma's Hair Loss Drug Approved by USFDA
26 Jul 2024|01:45 PM

The US Food and Drug Administration (USFDA) has approved LEQSELVI (deuruxolitinib) 8 mg tablets, according to a regulatory filing.

Read More
Mayne Pharma Sues Sun Pharma in Patent Dispute
25 Jul 2024|11:57 AM

IMVEXXY is a vaginal insert designed to lessen pain during sexual activity after menopause which is manufactured by Mayne Pharma.

Read More
USFDA grills Sun Pharma for manufacturing issues at Dadra facility
4 Jul 2024|11:24 AM

The warning letter detailed substantial violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals at the facility.

Read More
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.